# A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

> **NCT05945368** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 78 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Eribulin mesylate injection、Pertuzumab、Trastuzumab

## Key facts

- **NCT ID:** NCT05945368
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-25
- **Primary completion:** 2024-02-25
- **Final completion:** 2025-02-25
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05945368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05945368, "A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05945368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*